A Serial Analysis of Gene Expression (SAGE) Database Analysis of Chemosensitivity: Comparing Solid Tumors with Cell Lines and Comparing Solid Tumors from Different Tissue Origins

Cancer Research

Volumn 64, Issue 8, 2004, Pages 2805-2816

  Stein, Wilfred D ^a,c,d   Litman, Thomas ^b   Fojo, Tito ^c   Bates, Susan E ^c  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Bldg 10 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYTARABINE; DACARBAZINE; DOXORUBICIN; ESTRAMUSTINE; ETOPOSIDE; FLUOROURACIL; IRINOTECAN; LOMUSTINE; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; OXALIPLATIN; PACLITAXEL; TENIPOSIDE; TIOGUANINE; TOPOTECAN; VINBLASTINE; VINCRISTINE;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER REGISTRY; CANCER RESISTANCE; CANCER SURVIVAL; CELL ADHESION; CHEMOSENSITIVITY; COLON CANCER; CYTOTOXICITY; DATA BASE; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE IDENTIFICATION; GLIOMA; HUMAN; IMMUNE RESPONSE; MEDULLOBLASTOMA; METASTASIS; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN SYNTHESIS; SERIAL ANALYSIS OF GENE EXPRESSION; SOLID TUMOR;

CELL LINE, TUMOR; DATABASES, GENETIC; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION PROFILING; HUMANS; NEOPLASMS;

EID: 4444258440     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3383     Document Type: Article

References (60)

1. Guden M, Ulutin C, Goktas S. Analyses of 98 seminoma cases: a review article. Int Urol Nephrol 2001;33:529-31.
2. Spermon JR, Witjes JA, Kiemeney LA. Difference in stage and morphology-adjusted survival between young and elderly patients with a testicular germ cell tumor. Urology 2002;60:889-93.
3. Druker BJ. Current treatment approaches for chronic myelogenous leukemia. Cancer J. 29001;7 Suppl 1:S14-8.
4. Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med 2003;138:819-30.
5. Abbruzzese JL. Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality. Semin Oncol 2002;29:2-8.
6. el Kamar FG, Grossbard ML, Kozuch PS. Metastatic pancreatic cancer: emerging strategies in chemotherapy and palliative care. Oncologist 2003;8:18-34.
7. Dieckmann KP, Loy V. Response of metastasized sex cord gonadal stromal tumor of the testis to cisplatin-based chemotherapy. J Urol 1994;151:1024-6.
8. Carsky S, Ondrus D, Schnorrer M, Majek M. Germ cell testicular tumours with lung metastases: chemotherapy and surgical treatment. Int Urol Nephrol 1992;24:305-11.
9. Pizzocardo G, Salvioni R, Zanoni F, Milani A, Piva L. Successful treatment of good-risk disseminated testicular cancer with cisplatin, bleomycin, and reduced-dose vinblastine. Cancer (Phila) 1986;57:2114-8.
10. Zhang W, Laborde PM, Coombes KR, Berry DA, Hamilton SR. Cancer genomics: promises and complexities. Clin Cancer Res 2001;7:2159-67.
11. Staunton JE, Slonim DK, Coller HA, et al. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci USA 2001;98:10787-92.
12. Nutt CL, Mani DR, Betensky RA, et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 2003;63:1602-7.
13. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33:49-54.
14. Singh D, Febbo PG, Ross K, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002;1:203-9.
15. Ramaswamy S, Golub TR. DNA microarrays in clinical oncology. J Clin. Oncol 2002;20:1932-41.
16. Ramaswamy S, Tamayo P, Rifkin R, et al. Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci USA 2001;98:15149-54.
17. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001;98:13790-5.
18. Liotta LA, Kohn EC. Cancer's deadly signature. Nat Genet 2003;33:10-1.
19. Hampton GM, Frierson HF. Classifying human cancer by analysis of gene expression. Trends Mol Med 2003;9:5-10.
20. Cohen CD, Kretzler M. Gene expression analysis in microdissected renal tissue. Current challenges and strategies. Nephron 2002;92:522-8.
21. Velculescu VE, Zhang L, Vogelstein B, Kinzler KW. Serial analysis of gene expression. Science (Wash DC) 1995;270:484-7.
22. Nacht M, Ferguson AT, Zhang W, et al, Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer. Cancer Res 1999;59:5464-70.
23. Boon K, Osorio EC, Greenhut SF, et al. An anatomy of normal and malignant gene expression. Proc Natl Acad Sci USA 2002;99:11287-92.
24. Hilsenbeck SG, Friedrichs WE, Schiff R, et al. Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. J Natl Cancer Inst (Bethesda) 1999;91:453-9.
25. Ross DT, Scherf U, Eisen MB, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000;24:227-35.
26. Ries LAG, Eisner MP, Kosary CL, et al. SEER cancer statistics review, 1973-1999. Bethesda, MD: National Cancer Institute, 2002.
27. Monks A, Scudiero D, Skehan P, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst (Bethesda) 1991;83:757-66.
28. Dennis G Jr, Sherman BT, Hosack DA, et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol 2003;4:3.
29. Saha S, Sparks AB, Rago C, et al. Using the transcriptome to annotate the genome. Nat Biotechnol 2002;20:508-12.
30. Semino C, Martini L, Queirolo P, et al. Adoptive immunotherapy of advanced solid tumors: an eight year clinical experience. Anticancer Res 1999;19:5645-9.
31. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 2003;26:332-42.
32. Gumbiner BM. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell 1996;84:345-57.
33. Francois C, Moreno C, Teitelbaum J, et al. Improving accuracy in the grading of renal cell carcinoma by combining the quantitative description of chromatin pattern with the quantitative determination of cell kinetic parameters. Cytometry 2000;42:18-26.
34. Aaltomaa S, Lipponen P, Eskelinen M, Ala-Opas M, Kosma VM. Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer. Prostate 1999;39:8-15.
35. Watkins SJ, Norbury CJ. Translation initiation and its deregulation during tumorigenesis. Br J Cancer 2002;86:1023-7.
36. Eberle J, Fecker LF, Bitnner JU, Orfanos CE, Geilen CC. Decreased proliferation of human melanoma cell lines caused by antisense RNA against translation factor eIF-4A1. Br J Cancer 2002;86:1957-62.
37. DeVita VT, Hellman S, Rosenberg SA. Cancer: Principles and practice of oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2001.
38. Garrido SM, Appelbaum FR, Willman CL, Banker DE. Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol 2001;29:448-57.
39. Gottardi CJ, Gumbiner BM. Adhesion signaling: how β-catenin interacts with its partners. Curr Biol 2001;11:R792-4.
40. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994;124:619-26.
41. Orford K, Orford CC, Byers SW. Exogenous expression of β-catenin regulates contact inhibition, anchorage-independent growth, anoikis, and radiation-induced cell cycle arrest. J Cell Biol 1999;146:855-68.
42. Furukawa T, Kubota T, Hoffman RM. Clinical applications of the histoculture drug response assay. Clin Cancer Res 1995;1:305-11.
43. Weaver JR, Wientjes MG, Au JL. Regional heterogeneity and pharmacodynamics in human solid tumor histoculture. Cancer Chemother Pharmacol 1999;44:335-42.
44. Weaver JR, Gan Y, Au JL. Proliferation indices as molecular pharmacodynamic endpoints in evaluation of anticancer drug effect in human solid tumors. Pharm Res 1998;15:1546-51.
45. Margolis L, Hatfill S, Chuaqui R, et al. Long term organ culture of human prostate tissue in a NASA-designed rotating wall bioreactor. J Urol 1999;161:290-7.
46. Song S, Wientjes MG, Gan Y, Au JL. Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci USA 2000;97:8658-63.
47. 2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res 1997;57:2388-93.
48. L. Cancer Res 2001;61:4837-41.
49. Croix BS, Rak JW, Kapitain S, Sheehan C, Graham CH, Kerbel RS. Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. J Natl Cancer Inst (Bethesda) 1996;88:1285-96.
50. Green SK, Karlsson MC, Ravetch JV, Kerbel RS. Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer. Cancer Res 2002;62:6891-900.
51. Dalton, W. S. The tumor microenvironment: focus on myeloma. Cancer Treat Rev 2003;29 Suppl 1:11-9.
52. Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 2003;17:1175-82.
53. Naot D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res 1997;71:241-319.
54. Weber GF, Bronson RT, Ilagan J, Cantor H, Schmits R, Mak TW. Absence of the CD44 gene prevents sarcoma metastasis. Cancer Res 2002;62:2281-6.
55. O'Driscoll L, Linehan R, Liang YH, Joyce H, Oglesby I, Clynes M. Galectin-3 expression alters adhesion, motility and invasion in a lung cell line (DLKP), in vitro. Anticancer Res 2002;22:3117-25.
56. Miyazaki J, Hokari R, Kato S, et al. Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes. Oncol Rep 2002;9:1307-12.
57. Floyd S, De Camilli P. Endocytosis proteins and cancer: a potential link? Trends Cell Biol 1998;8:299-301.
58. Tucker E, Buda A, Janghra B, et al. Abnormalities of the cadherin-catenin complex in chemically-induced colo-rectal carcinogenesis. Proc Nutr Soc 2003;62:229-36.
59. Tamura I, Sakaki T, Chaqour B, Howard PS, Ikeo T, Macarak EJ. Correlation of P-cadherin and β-catenin expression and phosphorylation with carcinogenesis in rat tongue cancer induced with 4-nitroquinoline I-oxide. Oral Oncol 2003;39:506-14.
60. De La TA, Rubin MA, Chen MW, et al. beta-Catenin-related Anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clin Cancer Res 2003;9:1801-7.